Smith+Nephew earned 501(k) clearance from the FDA for its Catalystem Primary Hip System.
The system aims to tackle the changing needs and demands of primary hip surgery, including the expanding role of ambulatory surgery centers in hip procedures, according to a July 16 news release.
The Catalystem system is designed to be effective for direct anterior approach, which is becoming more common.
The direct anterior approach is a less invasive surgery, leading to improved range of motion and faster recovery times, the release said.